Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical ...

Alnylam said it was seeking damages over the use of lipid nanoparticle (LNP) technology used in the Pfizer/BioNTech and ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by Pfizer (PFE) and BioNTech (BNTX), marking the latest such case among ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...